| Theodore Mcmenomy, MD | |
|
45 10th St W, Saint Paul, MN 55102 | |
| (651) 232-3000 | |
| Not Available |
| Full Name | Theodore Mcmenomy |
|---|---|
| Gender | Male |
| Speciality | Critical Care (intensivists) |
| Experience | 19 Years |
| Location | 45 10th St W, Saint Paul, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1811036809 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Abbott Northwestern Hospital | Minneapolis, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Allina Health System | 4587573613 | 3071 |
News Archive
The New York Times examines the growing - and lucrative - practice among doctors to call in colleagues to consult during a surgery or afterward. The need is sometimes questionable, and patients often don't even know the second doctor was involved until the bill arrives.
Adamas Pharmaceuticals, Inc., a privately held company, announced today the results from the first clinical study evaluating triple combination antiviral drug (TCAD) therapy for the treatment of influenza A in immunocompromised patients. Data from this Phase 1b study were presented by clinical investigator Dr. Janet Englund in a clinical symposium at the 23rd International Conference on Antiviral Research (ICAR) in San Francisco.
By identifying new compounds that selectively block mitochondrial respiration in pathogenic fungi, Whitehead Institute scientists have identified a potential antifungal mechanism that could enable combination therapy with fluconazole, one of today's most commonly prescribed fungal infection treatments.
Lux Biosciences, Inc. today announced that the European Medicines Agency has accepted the filing of the company's Marketing Authorization Application (MAA) for the company's lead product, Luveniq™ (LX211; oral voclosporin) for the treatment of noninfectious uveitis involving the intermediate or posterior segments of the eye.
› Verified 1 days ago
| Entity Name | Fairview Health Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013994359 PECOS PAC ID: 1951213057 Enrollment ID: O20031105000461 |
News Archive
The New York Times examines the growing - and lucrative - practice among doctors to call in colleagues to consult during a surgery or afterward. The need is sometimes questionable, and patients often don't even know the second doctor was involved until the bill arrives.
Adamas Pharmaceuticals, Inc., a privately held company, announced today the results from the first clinical study evaluating triple combination antiviral drug (TCAD) therapy for the treatment of influenza A in immunocompromised patients. Data from this Phase 1b study were presented by clinical investigator Dr. Janet Englund in a clinical symposium at the 23rd International Conference on Antiviral Research (ICAR) in San Francisco.
By identifying new compounds that selectively block mitochondrial respiration in pathogenic fungi, Whitehead Institute scientists have identified a potential antifungal mechanism that could enable combination therapy with fluconazole, one of today's most commonly prescribed fungal infection treatments.
Lux Biosciences, Inc. today announced that the European Medicines Agency has accepted the filing of the company's Marketing Authorization Application (MAA) for the company's lead product, Luveniq™ (LX211; oral voclosporin) for the treatment of noninfectious uveitis involving the intermediate or posterior segments of the eye.
› Verified 1 days ago
| Entity Name | Healtheast Woodwinds Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356309322 PECOS PAC ID: 9638082563 Enrollment ID: O20031107000110 |
News Archive
The New York Times examines the growing - and lucrative - practice among doctors to call in colleagues to consult during a surgery or afterward. The need is sometimes questionable, and patients often don't even know the second doctor was involved until the bill arrives.
Adamas Pharmaceuticals, Inc., a privately held company, announced today the results from the first clinical study evaluating triple combination antiviral drug (TCAD) therapy for the treatment of influenza A in immunocompromised patients. Data from this Phase 1b study were presented by clinical investigator Dr. Janet Englund in a clinical symposium at the 23rd International Conference on Antiviral Research (ICAR) in San Francisco.
By identifying new compounds that selectively block mitochondrial respiration in pathogenic fungi, Whitehead Institute scientists have identified a potential antifungal mechanism that could enable combination therapy with fluconazole, one of today's most commonly prescribed fungal infection treatments.
Lux Biosciences, Inc. today announced that the European Medicines Agency has accepted the filing of the company's Marketing Authorization Application (MAA) for the company's lead product, Luveniq™ (LX211; oral voclosporin) for the treatment of noninfectious uveitis involving the intermediate or posterior segments of the eye.
› Verified 1 days ago
| Entity Name | Ridgeview Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528364429 PECOS PAC ID: 9234041997 Enrollment ID: O20031111000183 |
News Archive
The New York Times examines the growing - and lucrative - practice among doctors to call in colleagues to consult during a surgery or afterward. The need is sometimes questionable, and patients often don't even know the second doctor was involved until the bill arrives.
Adamas Pharmaceuticals, Inc., a privately held company, announced today the results from the first clinical study evaluating triple combination antiviral drug (TCAD) therapy for the treatment of influenza A in immunocompromised patients. Data from this Phase 1b study were presented by clinical investigator Dr. Janet Englund in a clinical symposium at the 23rd International Conference on Antiviral Research (ICAR) in San Francisco.
By identifying new compounds that selectively block mitochondrial respiration in pathogenic fungi, Whitehead Institute scientists have identified a potential antifungal mechanism that could enable combination therapy with fluconazole, one of today's most commonly prescribed fungal infection treatments.
Lux Biosciences, Inc. today announced that the European Medicines Agency has accepted the filing of the company's Marketing Authorization Application (MAA) for the company's lead product, Luveniq™ (LX211; oral voclosporin) for the treatment of noninfectious uveitis involving the intermediate or posterior segments of the eye.
› Verified 1 days ago
| Entity Name | Healtheast Medical Research Institute |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639125503 PECOS PAC ID: 3971407636 Enrollment ID: O20031124000507 |
News Archive
The New York Times examines the growing - and lucrative - practice among doctors to call in colleagues to consult during a surgery or afterward. The need is sometimes questionable, and patients often don't even know the second doctor was involved until the bill arrives.
Adamas Pharmaceuticals, Inc., a privately held company, announced today the results from the first clinical study evaluating triple combination antiviral drug (TCAD) therapy for the treatment of influenza A in immunocompromised patients. Data from this Phase 1b study were presented by clinical investigator Dr. Janet Englund in a clinical symposium at the 23rd International Conference on Antiviral Research (ICAR) in San Francisco.
By identifying new compounds that selectively block mitochondrial respiration in pathogenic fungi, Whitehead Institute scientists have identified a potential antifungal mechanism that could enable combination therapy with fluconazole, one of today's most commonly prescribed fungal infection treatments.
Lux Biosciences, Inc. today announced that the European Medicines Agency has accepted the filing of the company's Marketing Authorization Application (MAA) for the company's lead product, Luveniq™ (LX211; oral voclosporin) for the treatment of noninfectious uveitis involving the intermediate or posterior segments of the eye.
› Verified 1 days ago
| Entity Name | Healtheast St Joseph's Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134186273 PECOS PAC ID: 2365348869 Enrollment ID: O20031208000245 |
News Archive
The New York Times examines the growing - and lucrative - practice among doctors to call in colleagues to consult during a surgery or afterward. The need is sometimes questionable, and patients often don't even know the second doctor was involved until the bill arrives.
Adamas Pharmaceuticals, Inc., a privately held company, announced today the results from the first clinical study evaluating triple combination antiviral drug (TCAD) therapy for the treatment of influenza A in immunocompromised patients. Data from this Phase 1b study were presented by clinical investigator Dr. Janet Englund in a clinical symposium at the 23rd International Conference on Antiviral Research (ICAR) in San Francisco.
By identifying new compounds that selectively block mitochondrial respiration in pathogenic fungi, Whitehead Institute scientists have identified a potential antifungal mechanism that could enable combination therapy with fluconazole, one of today's most commonly prescribed fungal infection treatments.
Lux Biosciences, Inc. today announced that the European Medicines Agency has accepted the filing of the company's Marketing Authorization Application (MAA) for the company's lead product, Luveniq™ (LX211; oral voclosporin) for the treatment of noninfectious uveitis involving the intermediate or posterior segments of the eye.
› Verified 1 days ago
| Entity Name | Healtheast St John's Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447218482 PECOS PAC ID: 9234035742 Enrollment ID: O20031208000320 |
News Archive
The New York Times examines the growing - and lucrative - practice among doctors to call in colleagues to consult during a surgery or afterward. The need is sometimes questionable, and patients often don't even know the second doctor was involved until the bill arrives.
Adamas Pharmaceuticals, Inc., a privately held company, announced today the results from the first clinical study evaluating triple combination antiviral drug (TCAD) therapy for the treatment of influenza A in immunocompromised patients. Data from this Phase 1b study were presented by clinical investigator Dr. Janet Englund in a clinical symposium at the 23rd International Conference on Antiviral Research (ICAR) in San Francisco.
By identifying new compounds that selectively block mitochondrial respiration in pathogenic fungi, Whitehead Institute scientists have identified a potential antifungal mechanism that could enable combination therapy with fluconazole, one of today's most commonly prescribed fungal infection treatments.
Lux Biosciences, Inc. today announced that the European Medicines Agency has accepted the filing of the company's Marketing Authorization Application (MAA) for the company's lead product, Luveniq™ (LX211; oral voclosporin) for the treatment of noninfectious uveitis involving the intermediate or posterior segments of the eye.
› Verified 1 days ago
| Entity Name | Healtheast Care System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194787465 PECOS PAC ID: 7214833763 Enrollment ID: O20031208000483 |
News Archive
The New York Times examines the growing - and lucrative - practice among doctors to call in colleagues to consult during a surgery or afterward. The need is sometimes questionable, and patients often don't even know the second doctor was involved until the bill arrives.
Adamas Pharmaceuticals, Inc., a privately held company, announced today the results from the first clinical study evaluating triple combination antiviral drug (TCAD) therapy for the treatment of influenza A in immunocompromised patients. Data from this Phase 1b study were presented by clinical investigator Dr. Janet Englund in a clinical symposium at the 23rd International Conference on Antiviral Research (ICAR) in San Francisco.
By identifying new compounds that selectively block mitochondrial respiration in pathogenic fungi, Whitehead Institute scientists have identified a potential antifungal mechanism that could enable combination therapy with fluconazole, one of today's most commonly prescribed fungal infection treatments.
Lux Biosciences, Inc. today announced that the European Medicines Agency has accepted the filing of the company's Marketing Authorization Application (MAA) for the company's lead product, Luveniq™ (LX211; oral voclosporin) for the treatment of noninfectious uveitis involving the intermediate or posterior segments of the eye.
› Verified 1 days ago
| Entity Name | Minnesota Valley Health Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730248907 PECOS PAC ID: 9032006507 Enrollment ID: O20040301000309 |
News Archive
The New York Times examines the growing - and lucrative - practice among doctors to call in colleagues to consult during a surgery or afterward. The need is sometimes questionable, and patients often don't even know the second doctor was involved until the bill arrives.
Adamas Pharmaceuticals, Inc., a privately held company, announced today the results from the first clinical study evaluating triple combination antiviral drug (TCAD) therapy for the treatment of influenza A in immunocompromised patients. Data from this Phase 1b study were presented by clinical investigator Dr. Janet Englund in a clinical symposium at the 23rd International Conference on Antiviral Research (ICAR) in San Francisco.
By identifying new compounds that selectively block mitochondrial respiration in pathogenic fungi, Whitehead Institute scientists have identified a potential antifungal mechanism that could enable combination therapy with fluconazole, one of today's most commonly prescribed fungal infection treatments.
Lux Biosciences, Inc. today announced that the European Medicines Agency has accepted the filing of the company's Marketing Authorization Application (MAA) for the company's lead product, Luveniq™ (LX211; oral voclosporin) for the treatment of noninfectious uveitis involving the intermediate or posterior segments of the eye.
› Verified 1 days ago
| Entity Name | Allina Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295272342 PECOS PAC ID: 4587573613 Enrollment ID: O20040319000460 |
News Archive
The New York Times examines the growing - and lucrative - practice among doctors to call in colleagues to consult during a surgery or afterward. The need is sometimes questionable, and patients often don't even know the second doctor was involved until the bill arrives.
Adamas Pharmaceuticals, Inc., a privately held company, announced today the results from the first clinical study evaluating triple combination antiviral drug (TCAD) therapy for the treatment of influenza A in immunocompromised patients. Data from this Phase 1b study were presented by clinical investigator Dr. Janet Englund in a clinical symposium at the 23rd International Conference on Antiviral Research (ICAR) in San Francisco.
By identifying new compounds that selectively block mitochondrial respiration in pathogenic fungi, Whitehead Institute scientists have identified a potential antifungal mechanism that could enable combination therapy with fluconazole, one of today's most commonly prescribed fungal infection treatments.
Lux Biosciences, Inc. today announced that the European Medicines Agency has accepted the filing of the company's Marketing Authorization Application (MAA) for the company's lead product, Luveniq™ (LX211; oral voclosporin) for the treatment of noninfectious uveitis involving the intermediate or posterior segments of the eye.
› Verified 1 days ago
| Entity Name | Sibley Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740240225 PECOS PAC ID: 3870722499 Enrollment ID: O20140418000315 |
News Archive
The New York Times examines the growing - and lucrative - practice among doctors to call in colleagues to consult during a surgery or afterward. The need is sometimes questionable, and patients often don't even know the second doctor was involved until the bill arrives.
Adamas Pharmaceuticals, Inc., a privately held company, announced today the results from the first clinical study evaluating triple combination antiviral drug (TCAD) therapy for the treatment of influenza A in immunocompromised patients. Data from this Phase 1b study were presented by clinical investigator Dr. Janet Englund in a clinical symposium at the 23rd International Conference on Antiviral Research (ICAR) in San Francisco.
By identifying new compounds that selectively block mitochondrial respiration in pathogenic fungi, Whitehead Institute scientists have identified a potential antifungal mechanism that could enable combination therapy with fluconazole, one of today's most commonly prescribed fungal infection treatments.
Lux Biosciences, Inc. today announced that the European Medicines Agency has accepted the filing of the company's Marketing Authorization Application (MAA) for the company's lead product, Luveniq™ (LX211; oral voclosporin) for the treatment of noninfectious uveitis involving the intermediate or posterior segments of the eye.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Theodore Mcmenomy, MD 1690 University Ave W Ste 370, Saint Paul, MN 55104-3723 Ph: (651) 232-6905 | Theodore Mcmenomy, MD 45 10th St W, Saint Paul, MN 55102 Ph: (651) 232-3000 |
News Archive
The New York Times examines the growing - and lucrative - practice among doctors to call in colleagues to consult during a surgery or afterward. The need is sometimes questionable, and patients often don't even know the second doctor was involved until the bill arrives.
Adamas Pharmaceuticals, Inc., a privately held company, announced today the results from the first clinical study evaluating triple combination antiviral drug (TCAD) therapy for the treatment of influenza A in immunocompromised patients. Data from this Phase 1b study were presented by clinical investigator Dr. Janet Englund in a clinical symposium at the 23rd International Conference on Antiviral Research (ICAR) in San Francisco.
By identifying new compounds that selectively block mitochondrial respiration in pathogenic fungi, Whitehead Institute scientists have identified a potential antifungal mechanism that could enable combination therapy with fluconazole, one of today's most commonly prescribed fungal infection treatments.
Lux Biosciences, Inc. today announced that the European Medicines Agency has accepted the filing of the company's Marketing Authorization Application (MAA) for the company's lead product, Luveniq™ (LX211; oral voclosporin) for the treatment of noninfectious uveitis involving the intermediate or posterior segments of the eye.
› Verified 1 days ago
Wojciech Kraszkiewicz, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 640 Jackson St, Saint Paul, MN 55101 Phone: 651-254-3456 Fax: 651-254-9673 | |
Nicholas Charles Boysen, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 640 Jackson St, Saint Paul, MN 55101 Phone: 651-254-3456 Fax: 651-254-9673 | |
Nathan M Frink, MD Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 1690 University Ave W, Suite 570, Saint Paul, MN 55104 Phone: 651-232-4800 Fax: 651-232-4899 | |
Dr. Andrew Caraganis, MD Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 401 Phalen Blvd, Saint Paul, MN 55130 Phone: 651-254-7670 Fax: 651-254-7676 | |
Dr. Patrick George Manning, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 640 Jackson St, Saint Paul, MN 55101 Phone: 651-254-4887 Fax: 651-254-1603 | |
Anthony Williams, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 640 Jackson St, Saint Paul, MN 55101 Phone: 651-254-3456 Fax: 651-254-9673 | |
Samantha May Scheid, Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 401 Phalen Blvd, Saint Paul, MN 55130 Phone: 651-254-7980 |